Ortmann Olaf, Cufer Tanja, Dixon J Michael, Maass Nicolai, Marchetti Paolo, Pagani Olivia, Pronzato Paolo, Semiglazov Vladimir, Spano Jean-Philippe, Vrdoljak Eduard, Wildiers Hans
Department of Obstetrics and Gynecology, University of Regensburg, Caritas-Hospital St. Josef, Regensburg, Germany.
Breast. 2009 Feb;18(1):2-7. doi: 10.1016/j.breast.2008.10.002. Epub 2008 Nov 26.
Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone-sensitive early breast cancer compared with tamoxifen. However, AIs should not be used in premenopausal women because they can paradoxically increase estrogen secretion and may therefore stimulate tumor progression. In perimenopausal women undergoing treatment for breast cancer, it can be difficult to determine true menopausal status because adjuvant chemotherapy, tamoxifen, and gonadotropin-releasing hormone analogues can induce transient (or permanent) ovarian suppression. How can one determine whether these women are truly postmenopausal and therefore candidates for AI therapy? A panel of experts in the field of endocrine therapy in breast cancer met in Dubrovnik, Croatia, on October 23, 2006, to discuss this clinical dilemma. This report summarizes the conclusions and recommendations that arose from this discussion.
与他莫昔芬相比，芳香化酶抑制剂（AIs）辅助治疗可改善激素敏感性早期乳腺癌绝经后女性的预后。然而，AIs不应应用于绝经前女性，因为它们可能反常地增加雌激素分泌，从而可能刺激肿瘤进展。在接受乳腺癌治疗的围绝经期女性中，很难确定其真正的绝经状态，因为辅助化疗、他莫昔芬和促性腺激素释放激素类似物可导致短暂（或永久性）卵巢抑制。如何确定这些女性是否真的处于绝经后状态，从而适合接受AI治疗呢？2006年于10月23日在克罗地亚杜布罗夫尼克召开了一次乳腺癌内分泌治疗领域的专家小组会议，讨论这一临床难题。本报告总结了此次讨论得出的结论和建议。
